Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Finechemicals’ New Factory in Fukushima Goes Online April 25
April 25, 2012
- Ono Upwardly Revises Profit Forecasts for FY2011
April 25, 2012
- Hyperphosphatemia Treatment JTT-751 Demonstrates Non-Inferiority in PIII Study: JT, Torii
April 25, 2012
- Senju to Launch Strategic Product Aiphagan in May, Expecting Efficacy in Maintaining Field of Vision
April 24, 2012
- Astellas Senior VP Sato Shares Plans to Market Gonax Within Current Structure, MRs Dedicated to Cancer “a Future Issue”
April 24, 2012
- Wakamoto’s New Midterm Business Plan Calls for Operating, Ordinary Profits in Fiscal Year Ending March 2013
April 24, 2012
- Daiichi Sankyo to Market Ranbaxy Products in China
April 24, 2012
- Bayer Yakuhin to Set Up Committee to Promote Proper Use of Xarelto
April 23, 2012
- TPU Withdraws NDA for Aricept Transdermal Patch: Eisai
April 23, 2012
- Terapia Ranbaxy to Launch Fixed Dose Combination of Olmesartan, Amlodipine in Romania
April 23, 2012
- Daiichi Sankyo Looking to Establish “Base Treatment” Position for Memary
April 23, 2012
- Mylan, Fuso Settle with Kureha in Kremezin Generic Patent Litigation
April 20, 2012
- Kaketsuken and Astellas Enter Sales and Marketing Agreement for Inactivated Polio Combination Vaccine
April 20, 2012
- Meiji Seika Pharma Discontinues Development of Hepatitis C Drug
April 20, 2012
- Nexium No. 1 in Call Frequency in HP Market for 2nd Month in a Row: Rep Track Survey
April 20, 2012
- Bayer Yakuhin Launches Oral Factor Xa Inhibitor Xarelto
April 19, 2012
- Ono’s MS Treatment ONO-4641 Meets Primary Endpoint in PII Study
April 19, 2012
- Novartis Files for Add’l Indication of PAH for Glivec
April 19, 2012
- Takeda to Differentiate New ARB Azilva Stressing Its Strong Hypotensive Effects
April 19, 2012
- JPWA, NPhA Agree to 6-Month Limit on Price Negotiations; Wholesalers’ Resolution to Be Tested for 3rd Time
April 19, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…